MedPath

Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan (ULYSSES)

Recruiting
Conditions
Hemoptysis
Registration Number
NCT05634200
Lead Sponsor
University of Milan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Inclusion Criteria:<br><br> - =18 years old<br><br> - Haemoptysis of unknown origin<br><br> - Negative or non-diagnostic chest CT scan<br><br>Exclusion Criteria:<br><br> - Known bleeding lesions of the upper or lower respiratory airways<br><br> - Chest CT scan diagnostic for hemoptysis etiology<br><br> - Refusal to sign the informed consent<br><br> - Refusal of bronchoscopy

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the proportion of patients with haemoptysis and negative/non-diagnostic CT scans in whom bronchoscopy allows an aetiological (i.e., endoscopic and/or microbiological and/or anatomopathological) diagnosis
Secondary Outcome Measures
NameTimeMethod
To evaluate the proportion of patients in whom bronchoscopy may detect occult endobronchial neoplasms (not detected with chest CT scan);To evaluate the proportion of patients in whom bronchoscopy may identify the source of the bleeding;To evaluate the proportion of patients with haemoptysis and negative chest CT scan in whom bronchoscopic findings may induce variation in the treatment of the patients;To evaluate the proportion of patients with a negative bronchoscopy at baseline, in whom a an endoscopic examination performed during the follow-up for recurrent haemoptysis may allow an aetiological diagnosis;To evaluate the proportion of patients with a negative chest CT scan and bronchoscopy in whom lung cancer may be diagnosed during the follow-up;To evaluate the main clinical characteristics (e.g., severity of haemoptysis) of these patients, the rate and severity of symptom recurrence and the mortality rate after one year of follow-up.
© Copyright 2025. All Rights Reserved by MedPath